Celyad Oncology Investor Relations Material

Celyad Oncology SA is a Belgium-based clinical-stage biotechnology company focused on the development of cell therapy solutions for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, leveraging proprietary technologies to develop allogeneic and autologous approaches for the treatment of solid and hematologic tumors. Celyad Oncology conducts research and clinical trials in collaboration with academic and industry partners. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares are listed on the Euronext Brussels and the NASDAQ.